Irrespective of other markers, CD21(−/low) expression is mostly associated with an inability of B cells to mount an immune response [46] and in our study CD21(−/low)/CD38- expression is significantly associated with clinical outcome in DLBCL. The gene discussed is CD38; the disease is diffuse large B-cell lymphoma.